Aspire Biopharma Holdings

ASBP · NASDAQ

$8.80−$0.10 (−1.12%)TodayMarket closed ·
Prev close $8.90

About ASBP

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Employees
0
Headquarters
Humacao, New York
Listed
Feb 18, 2022
Sector
Health Care
Industry
Pharmaceuticals

Leadership

Aspire Biopharma Holdings executives
NameTitleSince
Surendra Ajjarapu—2023
Howard Doss——
Mayur Doshi——
Donald Fell——
Michael Peterson——
Avinash Wadhwani——

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.